PomegraCharles River Stock Jumps 6.3% After Investor Day Lifts 2026 Guidance
Why is Charles River Laboratories stock up today?
Charles River Laboratories (CRL) stock rose 6.3% to $294.80 on Thursday after Investor Day unveiled a Pathway to Purpose strategy and lifted 2026 EPS guidance to the upper end of its range.
Key numbers
| CRL stock move | +6.3% to $294.80+45.9% year-to-date; 52-week low was $144.26 |
|---|---|
| 2026 non-GAAP EPS (upper-end guidance) | ~$11.45Range was $11.15–$11.45 |
| 2026 non-GAAP operating margin | 21.0%–21.3%Long-term target ~24% by 2030 |
| 2027–2030 organic revenue CAGR target | 5%–7%vs flat-to-1% in 2026 |
| Create the Future program savings | >$300M cumulative2027–2030 via automation and AI tools |
| DSA segment book-to-bill ratio | 1.19xHighest in nearly 4 years; 3rd consecutive quarter above 1.0x |
What happened
Charles River Laboratories (CRL) stock rose 6.3% to $294.80 on Thursday after Investor Day unveiled a Pathway to Purpose strategy and lifted 2026 EPS guidance to the upper end of its range. The company now expects full-year 2026 non-GAAP earnings per share of approximately $11.45 — the top of its prior $11.15–$11.45 range — with an operating margin of 21.0%–21.3%. Its new plan targets 5%–7% annual revenue growth through 2030 and over $300 million in cumulative savings via the Create the Future program. The drug safety testing unit's bookings ratio hit 1.19 times new orders versus revenue — the best reading in nearly four years — signaling that biopharma clients are placing more work.
Why it matters
Charles River Laboratories is a major contract research organization for early-stage drug testing, so its bookings levels are a leading indicator of how much new medicine is being greenlit across the industry. A clearer recovery path matters because biotech companies have raised nearly $100 billion over the past year, putting fresh money behind drug programs that need testing. Investors who bet against the beaten-down contract research sector — short sellers — now face mounting losses as biopharma demand recovery accelerates faster than expected.
Who this affects
- MarketbullishMedium impact
- CRO short sellers face losses as biopharma demand returns.
- CompanybullishHigh impact
- Raised guidance and 2030 targets benefit CRL shareholders.
- CompetitorsmixedLow impact
- ICON and Fortrea also gained modestly in sector recovery.
- IndustrybullishMedium impact
- Biopharma recovery signals rising demand for contract research.
Charles River vs ICON, Medpace, Fortrea
How we got here
CRL stock enters prolonged decline as biopharma clients slash R&D budgets.
FY2025 results posted; initial 2026 guidance set at 0%–1% organic revenue growth.
Q1 2026 earnings: first reported revenue gain in multiple quarters, up 1.2%.
Q2 2026 results: organic revenue growth returns after a three-year industry decline.
Investor Day: Pathway to Purpose unveiled; 2026 guidance lifted to upper end.
What to watch
- Q3 2026 earnings: whether 1.19x book-to-bill converts to reported revenue growth.Q4 2026
- Create the Future program: first efficiency savings expected beginning 2027.2027-01-01
- DSA book-to-bill sustainability above 1.0x through year-end; any biopharma funding shift.2026-12-31
Educational content only. Not investment advice.
More briefsAll briefs →
Lyft Stock Falls 7% After Q3 Revenue Miss
Lyft (LYFT) closed at $16.53 as a $69.1M legal charge cut revenue to $1.82B, below the $1.92B forecast.
Axon Stock Sinks 17% After Earnings Miss, Guidance Cut
Axon (AXON) trimmed 2026 sales growth guidance to 30% and put $1.2B into drone maker Skydio the same day.
Lam Research Stock Jumps 10% After $25B Buyback
Lam Research (LRCX) rebounded as the chip index recovered from a 12% rout driven by AI-rule worries.